wehewehe
ʻIke ʻia kā mākou tofacitinib intermediate ʻo cis-1-benzyl-4-methyl-3-methylaminopiperidine dihydrochloride a loaʻa iā CAS helu 1062580-52-2.ʻO ka intermediate kahi mea nui i ka hana ʻana o tofacitinib, kahi lāʻau lapaʻau i hoʻohana ʻia no ka mālama ʻana i ka rheumatoid arthritis, psoriatic arthritis a me ulcerative colitis.Ma ke ʻano he kikowaena koʻikoʻi i ka synthesis o tofacitinib, koʻikoʻi kā mākou huahana i nā mea noiʻi lāʻau lapaʻau a me nā mea hana.
Hoʻopili pono ʻia kēia pūhui waena e hōʻoia i ka pae kiʻekiʻe o ka maʻemaʻe a me ka paʻa.Me kā mākou mau kaʻina hana ʻoihana hou a me nā ana hoʻomalu maikaʻi koʻikoʻi, hiki iā ʻoe ke hilinaʻi i kā mākou tofacitinib intermediates e hoʻokō i nā kūlana ʻoihana kiʻekiʻe no ka maʻemaʻe a me ke kūpaʻa.
ʻO Tofacitinib Intermediate (3R, 4R) -1-Benzyl-3- (Mmethylamino) -4-Mmethylpiperidine DiHClide he laulā o nā noi, e lilo ana ia i waiwai waiwai i ka noiʻi lāʻau lapaʻau a me kemika.Ke alakaʻi nei ʻoe i ka noiʻi hoʻonaʻauao a i ʻole ka hoʻomohala ʻana i nā lāʻau lapaʻau, hāʻawi kā mākou pūhui waena i nā hopena hilinaʻi a kūpono hoʻi i kāu mau pono kikoʻī.
E koho iā mākou
Loaʻa iā JDK nā hale hana papa mua a me nā lako hoʻokele maikaʻi, e hōʻoiaʻiʻo ana i ka lako paʻa o nā kikowaena API.Hōʻoia ka hui ʻoihana i ka R&D o ka huahana.E kūʻē i nā mea ʻelua, ke ʻimi nei mākou iā CMO & CDMO ma ka mākeke kūloko a me ka honua.